eprintid: 10057245
rev_number: 18
eprint_status: archive
userid: 608
dir: disk0/10/05/72/45
datestamp: 2018-10-01 16:56:31
lastmod: 2021-09-17 22:29:43
status_changed: 2018-10-01 16:56:31
type: article
metadata_visibility: show
creators_name: Woodward, HL
creators_name: Innocenti, P
creators_name: Cheung, KMJ
creators_name: Hayes, A
creators_name: Roberts, J
creators_name: Henley, AT
creators_name: Faisal, A
creators_name: Mak, GWY
creators_name: Box, G
creators_name: Westwood, IM
creators_name: Cronin, N
creators_name: Carter, M
creators_name: Valenti, M
creators_name: De Haven Brandon, A
creators_name: O'Fee, L
creators_name: Saville, H
creators_name: Schmitt, J
creators_name: Burke, R
creators_name: Broccatelli, F
creators_name: Van Montfort, RLM
creators_name: Raynaud, FI
creators_name: Eccles, SA
creators_name: Linardopoulos, S
creators_name: Blagg, J
creators_name: Hoelder, S
title: Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine (BOS172722)
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F85
note: This is an open access article published under an ACS AuthorChoice License (https://pubs.acs.org/page/policy/authorchoice_termsofuse.html), which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
abstract: Monopolar spindle 1 (MPS1) occupies a central role in mitosis and is one of the main components of the spindle assembly checkpoint. The MPS1 kinase is an attractive cancer target, and herein, we report the discovery of the clinical candidate BOS172722. The starting point for our work was a series of pyrido[3,4-d]pyrimidine inhibitors that demonstrated excellent potency and kinase selectivity but suffered from rapid turnover in human liver microsomes (HLM). Optimizing HLM stability proved challenging since it was not possible to identify a consistent site of metabolism and lowering lipophilicity proved unsuccessful. Key to overcoming this problem was the finding that introduction of a methyl group at the 6-position of the pyrido[3,4-d]pyrimidine core significantly improved HLM stability. Met ID studies suggested that the methyl group suppressed metabolism at the distant aniline portion of the molecule, likely by blocking the preferred pharmacophore through which P450 recognized the compound. This work ultimately led to the discovery of BOS172722 as a Phase 1 clinical candidate.
date: 2018-09-27
date_type: published
official_url: http://dx.doi.org/10.1021/acs.jmedchem.8b00690
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
article_type_text: Article
verified: verified_manual
elements_id: 1587767
doi: 10.1021/acs.jmedchem.8b00690
lyricists_name: Woodward, Hannah
lyricists_id: HKWOO61
actors_name: Dewerpe, Marie
actors_id: MDDEW97
actors_role: owner
full_text_status: public
publication: Journal of Medicinal Chemistry
volume: 61
number: 18
pagerange: 8226-8240
issn: 1520-4804
citation:        Woodward, HL;    Innocenti, P;    Cheung, KMJ;    Hayes, A;    Roberts, J;    Henley, AT;    Faisal, A;                                                                         ... Hoelder, S; + view all <#>        Woodward, HL;  Innocenti, P;  Cheung, KMJ;  Hayes, A;  Roberts, J;  Henley, AT;  Faisal, A;  Mak, GWY;  Box, G;  Westwood, IM;  Cronin, N;  Carter, M;  Valenti, M;  De Haven Brandon, A;  O'Fee, L;  Saville, H;  Schmitt, J;  Burke, R;  Broccatelli, F;  Van Montfort, RLM;  Raynaud, FI;  Eccles, SA;  Linardopoulos, S;  Blagg, J;  Hoelder, S;   - view fewer <#>    (2018)    Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine (BOS172722).                   Journal of Medicinal Chemistry , 61  (18)   pp. 8226-8240.    10.1021/acs.jmedchem.8b00690 <https://doi.org/10.1021/acs.jmedchem.8b00690>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10057245/1/acs.jmedchem.8b00690.pdf